exRNAdisease

General Information

Database ID:

exR0076890

RNA Name:

MLLT1

RNA Type:

mRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

6210381

End Site(bp):

6279975

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABHD17C	chr15	80679684	80755621	+
AC007192.1	chr19	18153158	18178117	+
AC010422.3	chr19	12643831	12648397	-
AC092073.1	chr19	34396315	34409364	+
ACIN1	chr14	23058564	23095614	-
ACTN4	chr19	38647649	38731589	+
ADCY3	chr2	24819169	24919839	-
AGRN	chr1	1020120	1056118	+
AKT2	chr19	40230317	40285536	-
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-34a-5p	chr1	9151735	9151756	-
hsa-miR-124-3p	chr8	64379210	64379231	+
hsa-miR-130a-3p	chr11	57641252	57641273	+
hsa-miR-149-5p	chr2	240456015	240456037	+
hsa-miR-302a-3p	chr4	112648186	112648208	-
hsa-miR-34c-5p	chr11	111513451	111513473	+
hsa-miR-130b-3p	chr22	21653354	21653375	+
hsa-miR-373-3p	chr19	53788748	53788770	+
hsa-miR-449a	chr5	55170586	55170607	-
hsa-miR-512-3p	chr19	53666729	53666750	+
hsa-miR-520e-3p	chr19	53675764	53675784	+
hsa-miR-520d-3p	chr19	53720149	53720170	+
hsa-miR-449b-5p	chr5	55170706	55170727	-
hsa-miR-654-5p	chr14	101040234	101040255	+
hsa-miR-454-3p	chr17	59137787	59137809	-
hsa-miR-483-5p	chr11	2134181	2134202	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC145285.6	chr16	28822431	28823969	-
AD000090.1	chr19	35557956	35581954	+
AF233439.1	chr8	6835535	6885276	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference